Jeffrey Tuan

Dr. Jeffrey Tuan


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2012 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
JTJeffrey Tuan
Jeffrey Tuan
THTam Cam Ha
Tam Cam Ha
WOWhee Sze Ong
Whee Sze Ong
TSTian Rui Siow
Tian Rui Siow
ITIvan Weng Keong Tham
Ivan Weng Keong Tham
JWJoseph Tien Seng Wee
Joseph Tien Seng Wee

17 November 2020 in Diagnostics
Verified
Journal Article
Open access
PDF file
TKTimo Kiljunen
Timo Kiljunen
SASaad Akram
Saad Akram
JNJarkko Niemelä
Jarkko Niemelä
ELEliisa Löyttyniemi
Eliisa Löyttyniemi
JSJan Seppälä
Jan Seppälä
JKJani Keyriläinen
Jani Keyriläinen
A commercial deep learning (DL)-based automated segmentation tool (AST) for computed tomography (CT) is evaluated for accuracy and efficiency gain within prostate cancer patients. Thirty patients from six clinics were reviewed with manual- (MC), automated- (AC) and automated and edited (AEC) contouring methods. In the AEC group, created contours (prostate, seminal vesicles, bladder, rectum, femoral heads and penile bulb) were edited, whereas the MC group included empty datasets for MC. In one clinic, lymph node CTV delineations were evaluated for interobserver variability. Compared to MC, the mean time saved using the AST was 12 min for the whole data set (46%) and 12 min for the lymph node CTV (60%), respectively. The delineation consistency between MC and AEC groups according to the Dice similarity coefficient (DSC) improved from 0.78 to 0.94 for the whole data set and from 0.76 to 0.91 for the lymph nodes. The mean DSCs between MC and AC for all six clinics were 0.82 for prostate, 0.72 for seminal vesicles, 0.93 for bladder, 0.84 for rectum, 0.69 for femoral heads and 0.51 for penile bulb. This study proves that using a general DL-based AST for CT images saves time and improves consistency.

11 March 2009 in Head & Neck
Verified
Journal Article
Closed access
PDF file
ITIvan Weng‐Keong Tham
Ivan Weng‐Keong Tham
SHSiew Wan Hee
Siew Wan Hee
SYSwee Peng Yap
Swee Peng Yap
JTJeffrey Tuan
Jeffrey Tuan
JWJoseph Wee
Joseph Wee

10 April 2013 in Cancer
Verified
Journal Article
Open access
PDF file
XCXingxing Chen
Xingxing Chen
XYXiaoli Yu
Xiaoli Yu
JCJiayi Chen
Jiayi Chen
ZZZhen Zhang
Zhen Zhang
JTJeffrey Tuan
Jeffrey Tuan
YFYan Feng
Yan Feng
BACKGROUND: The objective of this study was to evaluate and identify patterns of failure and prognostic factors for locoregional recurrence (LRR) that could justify postmastectomy radiotherapy after modified radical mastectomy in patients with early stage triple‐negative breast cancer.METHODS: Between January 2000 and July 2007, the authors retrospectively analyzed 390 patients who had triple‐negative breast cancer with T1/T2 tumors and from zero to 3 positive lymph nodes (pathologic T1‐T2N0‐N1) who underwent modified radical mastectomy without postmastectomy radiotherapy at the author's institution. The 5‐year cumulative incidence for events was calculated using Kaplan‐Meier analysis, and subgroups were compared using the log‐rank test. Multivariate analysis was performed using a Cox proportional hazards model.RESULTS: Overall, 86.4% of patients received chemotherapy. At a median follow‐up of 60.5 months, the 5‐year cumulative rates of local recurrence, regional recurrence, LRR, and distant metastasis were 5.4%, 4.7%, 8%, and 13.4%, respectively. On multivariate analysis, age <50 years, the presence of lymphovascular invasion, grade 3 tumor, and 3 involved lymph nodes were associated significantly with an increased risk of LRR. The 5‐year LRR rate for patients who had 0 or 1 risk factor, 2 risk factors, and 3 or 4 risk factors was 4.2%, 25.2%, and 81% (P < .0001), respectively. The presence of lymphovascular invasion and having 3 involved lymph nodes were statistically significant predictors of regional recurrence, and the patients who had regional recurrence had a significantly greater risk of distant metastases compared with patients who had local recurrence (59.1% vs 20.9%; P < .0001).CONCLUSIONS: Several risk factors were identified in this study that correlated independently with a greater incidence of LRR in patients who had early stage triple‐negative breast cancer. The current results indicated that postmastectomy radiotherapy should be considered for those patients who have 2 or more of these factors. Cancer 2013;119:2366‐2374. © 2013 American Cancer Society.

1 July 2013 in Journal of Radiation Research
Verified
Journal Article
Open access
PDF file
ASA. Srivastava
A. Srivastava
BVB. Vischioni
B. Vischioni
MFM. R. Fiore
M. R. Fiore
VVV. Vitolo
V. Vitolo
PFP. Fossati
P. Fossati
ROR. Orecchia
R. Orecchia
Introduction: Health-related quality of life (HQL) parameters have never been tested in patients having chondromas/chondrosarcomas who are being treated with protons. The aim of this study was to document changes in HQL of chordoma/chondrosarcoma patients treated with proton beam radiotherapy. Treatments commenced in September 2011 at CNAO, and HQL studies were initiated in January 2012 for all patients undergoing treatment. Methods: The validated Italian translation of the EORTC QLQ-C30 version 3.0 was used for HQL evaluation. The HQL assessments were made prior to starting radiation and at completion of treatment. Scoring was as per the EORTC manual. As per standard norms, a difference of >10 points in the mean scores was taken to be clinically meaningful. Results: Between January and September 2012, 17 patients diagnosed with chordoma or chondrosarcoma, with a mean ± SD age of 49.5 ± 16.4 years, had completed treatment. The involved sites were skull base (n = 12) and sacral/paraspinal (n = 5). The prescribed dose was 70–74 GyE at 2 GyE per fraction, 5 days/week. When comparing pre- and post-treatment scores, neither a clinically meaningful nor a statistically significant change was documented. Conclusions: During treatment, HQL is not adversely affected by protons, allowing normal life despite the long course of treatment. This is an ongoing study and more long-term assessment will help evaluate the actual impact of proton therapy on HQL for these slow-responding tumours.

17 September 2013 in Journal of Medical Ethics
Verified
Journal Article
Open access
PDF file
MSMark Sheehan
Mark Sheehan
CTClaire Timlin
Claire Timlin
KPKen Peach
Ken Peach
ABAriella Binik
Ariella Binik
PWPuthenparampil A. Wilson
Puthenparampil A. Wilson
CWCharles Weijer
Charles Weijer
The response to the dominance of the principle of patient choice has been slow in building but it has come in a number of ways. Two sets of papers in this issue of the Journal of Medical Ethics show just how far this response has come and the degree to which the pendulum is swinging back in the other direction. Neil Levy's Feature article, ‘Forced to be free? Increasing patient autonomy by constraining it’, argues that we should go to greater lengths to correct patients' mistaken decisions (see page 293, Editor's Choice). In the ‘Author meets critics’ section, Sarah Conly's book, Against Autonomy: Justifying Coercive Paternalism is the focus of comment (see page 349). Both authors draw on a similar range of empirical evidence to undermine the sanctity of patient and individual choice. An array of commentators draw on these target pieces to give a clear picture of the ways in which the popular view can justifiably be undermined.